20 April 2018 in Oncopediatrics
Background.Retinoblastoma (RB) is a life threatening cancer disease. A breakthrough in the treatment of children with RB is associated with the improvement of conservative treatment that was administered in at least one of the two tumor-affected eyes in most bilateral cases, that was chemotherapy both systemic and local (selective intra-arterial and intravitreal) in most cases combined with laser therapy, cryotherapy, or brachytherapy. The development of such techniques as local chemotherapy is focused on preservation of visual functions, reducing the number of enucleations and radiotherapy (RT) course. The success of the healing of RB is closely associated with a multidisciplinary approach to diagnosis and treatment, as well as specialized longterm follow-up clinical examination.Objective.eye and vision preservation against large intraocular tumors with different growth types and localization without the course of remote radiation therapy was the main purpose.Methods.In the period from September 2012 to January 2016, the study enrolled 45 patients with RB when at least one eye had intraocular tumor spread corresponding to the group C or D. According to the ABC international classification, patients have a relatively good prognosis for organ-preserving treatment. 4 of 18 children with bilateral RB had undergone primary enucleation of worse eye the worst eye, group E; 49 (77.8%) of the 63 affected eyes had features for groups C and D. In this study, no patient received local chemotherapy initially, only after prior systemic chemotherapy. Selective intra-arterial chemotherapy (SIAC) was applied to 41 patients (45 eyes; mean course number was 2), and 32 patients (34 eyes) had undergone intravitreal chemo therapy (IViC) (mean course number was 2). Focal therapy and local chemotherapy were the main methods of treatment for progression (new lesions on the retina) in 8 (16.3%) of 49 eyes with tumors of group C (n=1) and D (n=7); the relapse in 14 of 49 (new lesions on the retina) in eyes with tumors of group C (n=5) and D (n=6) and (new lesions on the retina and the vitreous) in eyes with tumors of group D (n=3) (28.5%), and stabilization of disease n=23 (46.9%). We should note that 2 patients underwent repeated course of in case of systemic chemotherapy, 1 patient — a Gamma Knife procedure due to registered disease stabilization, progression or relapse.Results.10 (20.4%) of 49 eyes saved due to the combined chemotherapy. In 45 patients diseasefree survival rate was 56.1±8.9 % (with mean follow-up period 26.9±2.5 months). 1 of 45 patients died from leukemia. 44 of 45 patients are alive without metastasis. The mean follow-up was 20 months (3 to 43 months). Eye salvage rate in group C — 14 (93.3%) of 15, in group D — 31 (91.2%) of 34.Conclusion.These methods: second line of systemic chemotherapy, RT, and a Gamma Knife procedure should be considered as a failure of primary treatment. Our study demonstrated a high efficacy of local chemotherapy with promissing techniques of conservation therapy, which safety increases due to experience.
25 September 2024 in American Journal of Ophthalmology
SCSandro Casavilca-Zambrano
Sandro Casavilca-Zambrano
+27
1 December 2019 in Russian Journal of Biotherapy
Introduction. The main reason for enucleation of the eye when attempting organ-preserving treatment are intraocular tumors that do not respond well to chemotherapy.Purpose. The aim of the study was to find new effective and safe organ-preserving methods of treatment of intraocular refractory and recurrent retinoblastoma (RB).Materials and methods. The study included female chinchilla rabbits. The cell line of human RB was intravitreally inserted into the right eye of each animal. The left eye was a control. After obtaining a stable intraocular growth of RB and prolongation of the growth of RB, human cytotoxic lymphocytes (CTL) were intravitreally injected into the affected and control eye K1 at a concentration of 1 × 106 in 0.1 ml suspension and K2 – 5 × 106 in 0.1 ml, respectively.Results. Histological examination of the removed right eyes in animals confirmed the presence of nodal growth of malignant small-cell tumor on the border of the vascular and retinal membranes (epicenter in the choroid) on the posterior wall of the eye. There was scant lymphoid infiltration, without signs of therapeutic pathomorphosis. In the removed animal»s left eyes there is a preservation of histological structures of the eyeball, without dystrophic changes in the cells of the retina and vascular membranes. In the area of limb unit microcap lymphohistiocytic infiltration (with no elements of the tumor). In the choroid single scattered lymphocytes.Conclusion. A short period of observation of the tumor did not allow conclusions about the effectiveness of CTL, but the concentrations of CTL used in the experiment did not lead to dystrophic changes in retinal cells and the choroid of the eye, which is an important factor in overcoming the toxicity of the proposed adoptive immunotherapy. At the next stage of the experiment, in our opinion, it is necessary to study in more detail the cytotoxic effect on healthy structures of the eye and the effectiveness of CTL in a larger number of affected rabbit eyes, using their different concentrations and multiplicity of administration.
30 October 2024 in Russian Journal of Pediatric Hematology and Oncology
Trilateral retinoblastoma (TRb) phenomenon is a combination of bilateral retinoblastoma (Rb) (in most cases) and molecular group A pineoblastoma (Pb).The study of this phenomenon has been going on for more than 30 years, is interdisciplinary in nature and includes two conceptual points of view from the positions of ophthalmic oncology and neurooncology.The frequency of this phenomenon detection varies from 0.75 to 2 % in the entire research group and from 2.1 to 3.5 % in the structure of bilateral forms. Intraocular lesions were presented by a bilateral variant in 91.5 % of clinical cases. Intracranial tumor in the pineal gland projection was detected in 73.3 % of cases, suprasellar localization – in 20 %. The ratio of synchronous and metachronous disease variants is heterogeneous and multidirectional and varies from 1,3:1 (according to large retrospective and prospective studies of Y. Zhang, X. Fang, T. Gui, S. Qureshi et al.) to 1:2,1–1:4 (according to meta-analysis of M.C. DeJong, R. Yamanaka et al.). All TRb cases were detected before the age of 60 months; the synchronous variant was detected before the age of 36 months in most clinical cases.Morphological and molecular biological study of the tumor substrate in children with TRb is currently disjointed in relation to the intraocular and intracranial segments of this phenomenon, Rb and Pb respectively.The most significant characteristics presented by determination of the germline RB1 gene mutation in blood samples, assessment of RB1, TFF1 proteins expression, a variant of the mutational event in the RB1 gene, the presence of N-MYC gene amplification, 1q gain, 16q loss in the tumor substrate of intraocular and/or pineal/suprasellar localization.In the treatment of children with the TRb phenomenon, both complex protocols and individual therapy programs are used. The optimal therapeutic strategy is unknown.